Skip Navigation
  • The Center for Hematologic Oncology at Dana-Farber/Brigham and Women's Cancer Center is one of the largest programs in the U.S. for patients with hematologic malignancies. We see more than 12,500 patients each year from around the world, and we offer specialized expertise in:

    • Acute and chronic leukemia
    • Chronic lymphocytic leukemia (CLL)
    • Aggressive lymphoma
    • Low-grade lymphoma
    • Mastocytosis
    • Autologous and allogeneic stem cell transplant
    • Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
    • Histiocytosis
    • Multiple myeloma
    • Precursor conditions
    • Waldenström's macroglobulinemia
    • Cellular therapies such as CAR T-cell therapy

    Our faculty and staff are actively engaged in basic, translational, and clinical research to improve outcomes and quality of life for patients. We offer more than 200 clinical trials evaluating new therapies — making us the first to offer the most promising treatments to patients.

    Why Choose DF/BWCC for Stem Cell Transplant or CAR T-Cell Therapy

    Our Stem Cell Transplant and Cellular Therapies Program has more than 45 years of experience and is one of the largest in the world, having performed more than 9,200 transplants. This experience makes a difference:

    • In-depth knowledge: We understand how to manage the complex treatment plans and unique needs associated with transplant and other cellular therapies.
    • Extensive evaluation: Our team carefully evaluates each patient to determine if stem cell transplant or CAR T-cell therapy is appropriate.
    • Exceptional outcomes: Our stem cell transplant outcomes consistently exceed the expected outcomes as established by the Center for International Blood and Marrow Transplant Research (CIBMTR).
    • Large team: We have more than 35 transplant-credentialed physicians. All are Harvard Medical School faculty members.
    • Disease-specific expertise: We offer stem cell transplant for many types of blood cancer and blood disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes, aplastic anemia, sickle cell disease, and more. Learn more about the diseases we treat with stem cell transplant.
    • Novel approaches: Our Center was one of the first to offer CAR T-cell therapy clinical trials for non-Hodgkin lymphoma; we now offer all FDA-approved CAR T-cell therapies, as well as clinical trials exploring this treatment for other types of blood cancer, such as leukemia, other types of lymphoma, and multiple myeloma.
    • State-of-the-art, in-house cell processing lab: The Connell and O'Reilly Families Cell Manipulation Core Facility is a critical component to our program, processing cellular products for stem cell transplant and CAR T-cell therapies.
    • Strong partnerships: Dana-Farber partners with Brigham and Women's Hospital, one of the nation's leading hospitals, to care for patients. In addition to a dedicated transplant or cellular therapy physician and nurse practitioner, patient care may include expert specialists in infectious disease, dermatology, neurology, pulmonology, and more – all with a deep understanding of the complex needs and complications of patients receiving these advanced therapies.

    What We Offer to International Patients

    From exceptional medical care to support with housing and other logistics, we offer many services to international patients:

    Program Leaders

    Our physician, nursing, and administrative teams are leaders in national and international organizations, working to influence policy and improve standards of care.

    Stem Cell Transplant Leadership

    Robert J. Soiffer, MD
    Chief, Division of Hematologic Malignancies
    Co-Chief, Stem Cell Transplant Program

    Joseph Antin, MD
    Chief, Stem Cell Transplant Program

    Vincent Ho, MD
    Clinical Director, Stem Cell Transplant Program

    Edwin Alyea, III, MD
    Associate Director, Stem Cell Transplant Program

    Amy Emmert, MScPH
    Vice President, Stem Cell Transplant and Cellular Therapies

    Janet Bagley, RN, MS
    Associate Chief Nurse

    Meet Our Stem Cell Transplant Team.

    Cellular Therapies Leadership

    Robert J. Soiffer, MD
    Chief, Division of Hematologic Malignancies Co-Chief, Stem Cell Transplant Program

    Caron Jacobson, MD
    Medical Director, Immune Effector Cell Therapy Program

    Sarah Nikiforow, MD, PhD
    Technical Director, Immune Effector Cell Therapy Program
    Assistant Medical Director, Connell and O'Reilly Families Cell Manipulation Core Facility

    Jerome Ritz, MD
    Executive Director, Connell and O'Reilly Families Cell Manipulation Core Facility

    Lauren Spendley, NP
    Program Manager, Immune Effector Cell Therapy Program

    How to Refer a Patient

    We work with our partners in the Brigham and Women's Hospital International Office to coordinate referrals for international patients. Contact us to inquire about an appointment:

    Phone: +1-617-732-5777
    Fax: +1-617-264-5100
    Email: brighamandwomensintl@bwh.harvard.edu

    Post-Treatment Care and Coordination

    Care for stem cell transplant or CAR T-cell therapy patients continues long after they are discharged from the hospital and return home to your care. We provide physicians with post-discharge care guidelines that outline recommended testing, symptoms to monitor, re-immunizations, and more — all to help you care for your returning patients. And our physicians will remain available to consult with you and answer any questions about post-discharge care.